{ "run": { "id": "cmnr13hia03hep658841u5gsy", "region": "US", "assetId": "cmnr13hhs03hap658es7g7oe0", "ticker": "ELV", "snapshotId": "cmnr13hi103hcp6588pvye90g", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:32.864Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr13hi103hcp6588pvye90g", "assetId": "cmnr13hhs03hap658es7g7oe0", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 318.23, "dayLow": 314.015, "volume": 1108833, "dayHigh": 319.38, "currency": "USD", "prevClose": 311.83, "week52Low": 273.71, "week52High": 458.75 }, "fundamentals": { "pe": 13.8666930379747, "beta": 0.443719419916541, "epsTTM": 25.28, "fcfTTM": 2717000000, "growth": { "epsYoy": -0.02053467648198364, "revenueYoy": 0.1249300890905085 }, "sector": "Hospital & Medical Service Plans", "margins": { "net": 0.02843440050219711, "gross": null, "operating": 0.03615317011927181 }, "website": "http://elevancehealth.com", "industry": "Managed healthcare", "pegRatio": -6.75281787377602, "ebitdaTTM": 9977000000, "forwardPe": 13.7094251075479, "marketCap": 87349478366, "totalCash": 9491000000, "totalDebt": 32046000000, "debtEquity": 0.730276651018641, "quickRatio": 0.8620689655172413, "revenueTTM": 199125000000, "companyName": "Elevance Health, Inc.", "priceToBook": 1.78356425748421, "currentRatio": 1.535299134884854, "dividendYield": 0.0195483627768608, "returnOnAssets": 0.04660312443412844, "returnOnEquity": 0.12902784740896, "analystOpinions": null, "businessSummary": "Elevance Health, Inc. is an American health insurance company. Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon. It is the largest for-profit managed health care company in the Blue Cross Blue Shield Association. As of 2022, the company had 46.8 million members within its affiliated companies' health plans.", "enterpriseValue": 101078200000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 104200, "sharesOutstanding": 220704667, "enterpriseToEbitda": 10.13112157963316, "analystTargetMedian": null, "enterpriseToRevenue": 0.5076118016321406, "operatingCashflowTTM": 4290000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:32.857Z" }, "results": [ { "id": "cmnr13hid03hgp658cwwuiowe", "runId": "cmnr13hia03hep658841u5gsy", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-3.7-sonnet-ai-equity-research\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"ELV\",\"currency\":\"USD\",\"current_price\":318.23,\"target_price_6m\":348,\"target_price_12m\":368,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Valuation at ~14x P/E is historically cheap for large-cap managed care\",\"Revenue growth of 12.5% YoY demonstrates strong top-line momentum\",\"Margin compression from elevated medical costs appears largely priced in\",\"Carelon services diversification provides long-term earnings growth optionality\",\"Stock 31% below 52-week high creates asymmetric risk-reward at current levels\"],\"key_drivers\":[{\"driver\":\"Medical cost trend normalization and MLR improvement\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medicare Advantage membership growth and rate adequacy\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medicaid redetermination churn headwinds fading\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Carelon services scaling and margin contribution\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share buyback support at depressed valuation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Persistent elevated medical utilization trends\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory and political risk on MA rate cuts\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"EPS declining YoY despite revenue growth signals margin pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Rising debt levels with $32B total debt\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Sustained medical cost inflation compressing margins beyond current expectations\",\"CMS Medicare Advantage rate cuts or unfavorable regulatory changes\",\"Medicaid contract losses or unfavorable state-level policy shifts\",\"Cybersecurity incidents impacting operations or claims processing\",\"Competitive pressure from vertical integration by UNH and CVS/Aetna\"],\"assumptions\":{\"revenue_cagr_3y\":0.08,\"ebit_margin_target\":0.042,\"wacc\":0.09,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":280,\"prob\":0.2,\"notes\":\"Medical costs remain elevated, EPS drops to ~$23, P/E compresses to 12x.\"},\"base\":{\"target_price\":368,\"prob\":0.55,\"notes\":\"Gradual margin recovery, EPS ~$26, P/E normalizes to ~14.5x.\"},\"bull\":{\"target_price\":440,\"prob\":0.25,\"notes\":\"Strong MLR improvement, EPS recovers to ~$28, P/E re-rates to 16x.\"}},\"method_notes\":\"Earnings-power valuation using normalized EPS and historical P/E range for managed care. ELV trades at a significant discount to 5-year average P/E (~17x), reflecting real margin headwinds. Base assumes partial operating margin recovery from 3.6% to ~4.2% over 12M. Revenue CAGR of 8% reflects MA/Medicaid/commercial growth mix. Forward P/E of 13.7 from snapshot implies Street EPS ~$23.2, suggesting further downside risk to earnings. BUY based on ~15.6% base-case upside, but confidence moderate given margin uncertainty. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "claude-3.7-sonnet-ai-equity-research", "risks": [ "Sustained medical cost inflation compressing margins beyond current expectations", "CMS Medicare Advantage rate cuts or unfavorable regulatory changes", "Medicaid contract losses or unfavorable state-level policy shifts", "Cybersecurity incidents impacting operations or claims processing", "Competitive pressure from vertical integration by UNH and CVS/Aetna" ], "ticker": "ELV", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Gradual margin recovery, EPS ~$26, P/E normalizes to ~14.5x.", "target_price": 368 }, "bear": { "prob": 0.2, "notes": "Medical costs remain elevated, EPS drops to ~$23, P/E compresses to 12x.", "target_price": 280 }, "bull": { "prob": 0.25, "notes": "Strong MLR improvement, EPS recovers to ~$28, P/E re-rates to 16x.", "target_price": 440 } }, "confidence": 0.64, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.08, "terminal_multiple": 14.5, "ebit_margin_target": 0.042 }, "key_drivers": [ { "driver": "Medical cost trend normalization and MLR improvement", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare Advantage membership growth and rate adequacy", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicaid redetermination churn headwinds fading", "impact": "MED", "direction": "POS" }, { "driver": "Carelon services scaling and margin contribution", "impact": "MED", "direction": "POS" }, { "driver": "Share buyback support at depressed valuation", "impact": "MED", "direction": "POS" }, { "driver": "Persistent elevated medical utilization trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory and political risk on MA rate cuts", "impact": "MED", "direction": "NEG" }, { "driver": "EPS declining YoY despite revenue growth signals margin pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Rising debt levels with $32B total debt", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Earnings-power valuation using normalized EPS and historical P/E range for managed care. ELV trades at a significant discount to 5-year average P/E (~17x), reflecting real margin headwinds. Base assumes partial operating margin recovery from 3.6% to ~4.2% over 12M. Revenue CAGR of 8% reflects MA/Medicaid/commercial growth mix. Forward P/E of 13.7 from snapshot implies Street EPS ~$23.2, suggesting further downside risk to earnings. BUY based on ~15.6% base-case upside, but confidence moderate given margin uncertainty. Not investment advice.", "current_price": 318.23, "recommendation": "BUY", "thesis_bullets": [ "Valuation at ~14x P/E is historically cheap for large-cap managed care", "Revenue growth of 12.5% YoY demonstrates strong top-line momentum", "Margin compression from elevated medical costs appears largely priced in", "Carelon services diversification provides long-term earnings growth optionality", "Stock 31% below 52-week high creates asymmetric risk-reward at current levels" ], "target_price_6m": 348, "target_price_12m": 368 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 46459, "createdAt": "2026-04-09T05:20:32.864Z", "usage": { "inputTokens": 3652, "outputTokens": 2213, "costUsd": 0.073585 } }, { "id": "cmnr13hid03hjp658a6spplem", "runId": "cmnr13hia03hep658841u5gsy", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Discounted Cash Flow with Scenario Analysis\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"ELV\",\n \"currency\": \"USD\",\n \"current_price\": 318.23,\n \"target_price_6m\": 344.0,\n \"target_price_12m\": 372.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Revenue growth supported by healthcare demand.\",\n \"Margin expansion from operational efficiencies.\",\n \"Defensive stock with low beta.\",\n \"EPS recovery expected post-investment phase.\",\n \"Attractive valuation vs. historical multiples.\"\n ],\n \"key_drivers\": [\n {\"driver\": \"Membership growth\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Medical cost inflation\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Regulatory environment\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Service integration (Carelon)\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Debt management\", \"impact\": \"LOW\", \"direction\": \"POS\"},\n {\"driver\": \"Technology adoption\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Competitive pressures\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\n \"Increased medical claims costs\",\n \"Changes in healthcare policy\",\n \"Economic recession impacting enrollment\",\n \"Cybersecurity incidents\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.04,\n \"wacc\": 0.056,\n \"terminal_multiple\": 14\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 300.0, \"prob\": 0.2, \"notes\": \"Lower growth and margin pressure.\"},\n \"base\": {\"target_price\": 372.0, \"prob\": 0.6, \"notes\": \"Steady execution on current plans.\"},\n \"bull\": {\"target_price\": 400.0, \"prob\": 0.2, \"notes\": \"Faster growth and cost savings.\"}\n },\n \"method_notes\": \"DCF valuation based on earnings growth and margin assumptions; BUY due to ~17% expected upside over 12 months. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Discounted Cash Flow with Scenario Analysis", "risks": [ "Increased medical claims costs", "Changes in healthcare policy", "Economic recession impacting enrollment", "Cybersecurity incidents" ], "ticker": "ELV", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution on current plans.", "target_price": 372 }, "bear": { "prob": 0.2, "notes": "Lower growth and margin pressure.", "target_price": 300 }, "bull": { "prob": 0.2, "notes": "Faster growth and cost savings.", "target_price": 400 } }, "confidence": 0.65, "assumptions": { "wacc": 0.056, "revenue_cagr_3y": 0.08, "terminal_multiple": 14, "ebit_margin_target": 0.04 }, "key_drivers": [ { "driver": "Membership growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical cost inflation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory environment", "impact": "MED", "direction": "NEG" }, { "driver": "Service integration (Carelon)", "impact": "MED", "direction": "POS" }, { "driver": "Debt management", "impact": "LOW", "direction": "POS" }, { "driver": "Technology adoption", "impact": "MED", "direction": "POS" }, { "driver": "Competitive pressures", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF valuation based on earnings growth and margin assumptions; BUY due to ~17% expected upside over 12 months. Not investment advice.", "current_price": 318.23, "recommendation": "BUY", "thesis_bullets": [ "Revenue growth supported by healthcare demand.", "Margin expansion from operational efficiencies.", "Defensive stock with low beta.", "EPS recovery expected post-investment phase.", "Attractive valuation vs. historical multiples." ], "target_price_6m": 344, "target_price_12m": 372 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 571, "createdAt": "2026-04-09T05:20:32.864Z", "usage": { "inputTokens": 2163, "outputTokens": 3478, "costUsd": 0.002066 } }, { "id": "cmnr13hid03hhp658wxmjjkvf", "runId": "cmnr13hia03hep658841u5gsy", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"ELV_Equity_Model_v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"ELV\",\n \"currency\": \"USD\",\n \"current_price\": 318.23,\n \"target_price_6m\": 360.00,\n \"target_price_12m\": 395.00,\n \"recommendation\": \"STRONG_BUY\",\n \"confidence\": 0.80,\n \"thesis_bullets\": [\n \"Valuation is highly attractive at 13.9x P/E, below historical averages despite solid revenue growth.\",\n \"Carelon health services segment provides a high-margin growth engine diversifying away from traditional premiums.\",\n \"Medicaid redetermination headwinds are largely priced in, setting up easier comps for the next year.\",\n \"Strong free cash flow generation supports consistent dividend growth and opportunistic share repurchases.\",\n \"Medicare Advantage rate pressures remain a risk, but scale allows ELV to navigate better.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Medical Loss Ratio (MLR) trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Carelon segment revenue growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medicare Advantage rate updates\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Medicaid membership retention\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Share repurchase program\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Commercial pricing power\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Value-based care adoption\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Higher-than-expected utilization driving up the Medical Loss Ratio (MLR).\",\n \"Adverse regulatory changes to Medicare Advantage reimbursement rates.\",\n \"Steeper membership losses from ongoing Medicaid redeterminations.\",\n \"Increased competition in the commercial employer-sponsored insurance market.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.045,\n \"wacc\": 0.075,\n \"terminal_multiple\": 14.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 280.00,\n \"prob\": 0.20,\n \"notes\": \"Elevated MLR and harsh Medicare Advantage rate cuts compress margins and multiple.\"\n },\n \"base\": {\n \"target_price\": 395.00,\n \"prob\": 0.60,\n \"notes\": \"Carelon growth and stable commercial pricing drive EPS expansion to historical 15x P/E.\"\n },\n \"bull\": {\n \"target_price\": 450.00,\n \"prob\": 0.20,\n \"notes\": \"Utilization normalizes quickly, driving significant margin expansion and multiple re-rating to 17x.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 10-year DCF (7.5% WACC) and target 15x P/E on NTM EPS. The 24% upside justifies a STRONG_BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ELV_Equity_Model_v1", "risks": [ "Higher-than-expected utilization driving up the Medical Loss Ratio (MLR).", "Adverse regulatory changes to Medicare Advantage reimbursement rates.", "Steeper membership losses from ongoing Medicaid redeterminations.", "Increased competition in the commercial employer-sponsored insurance market." ], "ticker": "ELV", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Carelon growth and stable commercial pricing drive EPS expansion to historical 15x P/E.", "target_price": 395 }, "bear": { "prob": 0.2, "notes": "Elevated MLR and harsh Medicare Advantage rate cuts compress margins and multiple.", "target_price": 280 }, "bull": { "prob": 0.2, "notes": "Utilization normalizes quickly, driving significant margin expansion and multiple re-rating to 17x.", "target_price": 450 } }, "confidence": 0.8, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.065, "terminal_multiple": 14.5, "ebit_margin_target": 0.045 }, "key_drivers": [ { "driver": "Medical Loss Ratio (MLR) trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Carelon segment revenue growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare Advantage rate updates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Medicaid membership retention", "impact": "MED", "direction": "NEG" }, { "driver": "Share repurchase program", "impact": "MED", "direction": "POS" }, { "driver": "Commercial pricing power", "impact": "MED", "direction": "POS" }, { "driver": "Value-based care adoption", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a blend of 10-year DCF (7.5% WACC) and target 15x P/E on NTM EPS. The 24% upside justifies a STRONG_BUY rating. Not investment advice.", "current_price": 318.23, "recommendation": "STRONG_BUY", "thesis_bullets": [ "Valuation is highly attractive at 13.9x P/E, below historical averages despite solid revenue growth.", "Carelon health services segment provides a high-margin growth engine diversifying away from traditional premiums.", "Medicaid redetermination headwinds are largely priced in, setting up easier comps for the next year.", "Strong free cash flow generation supports consistent dividend growth and opportunistic share repurchases.", "Medicare Advantage rate pressures remain a risk, but scale allows ELV to navigate better." ], "target_price_6m": 360, "target_price_12m": 395 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 21837, "createdAt": "2026-04-09T05:20:32.864Z", "usage": { "inputTokens": 2528, "outputTokens": 902, "costUsd": 0.01588 } }, { "id": "cmnr13hid03hfp6580hztiv2e", "runId": "cmnr13hia03hep658841u5gsy", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"ELV\",\"currency\":\"USD\",\"current_price\":318.23,\"target_price_6m\":338,\"target_price_12m\":356,\"recommendation\":\"BUY\",\"confidence\":0.66,\"thesis_bullets\":[\"Low-teens valuation already discounts utilization and Medicaid mix pressure.\",\"Medicaid recertification headwinds should moderate over the next year.\",\"Carelon adds service-driven earnings beyond core insurance underwriting.\",\"Medical cost trend remains the key swing factor for margins.\",\"Strong cash generation and dividend support downside resilience.\"],\"key_drivers\":[{\"driver\":\"Medicaid redetermination normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medicare Advantage utilization trend\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Premium rate repricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Carelon services growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Commercial membership retention\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulatory reimbursement changes\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Low forward valuation rerating\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Balance sheet leverage\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Higher-than-expected medical loss ratios\",\"Adverse Medicare or Medicaid rate actions\",\"Membership losses in key state contracts\",\"Regulatory or antitrust scrutiny\",\"Execution missteps in Carelon integration\"],\"assumptions\":{\"revenue_cagr_3y\":0.075,\"ebit_margin_target\":0.041,\"wacc\":0.085,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":285,\"prob\":0.25,\"notes\":\"Utilization stays elevated and repricing lags cost trend.\"},\"base\":{\"target_price\":356,\"prob\":0.5,\"notes\":\"Margins stabilize as Medicaid pressure eases and services grow.\"},\"bull\":{\"target_price\":410,\"prob\":0.25,\"notes\":\"Utilization normalizes faster and valuation rerates toward historical ranges.\"}},\"method_notes\":\"Used snapshot quote/fundamentals as authoritative. 12M target is an earnings-power valuation with modest margin recovery and ~14.5x multiple, cross-checked to EV/EBITDA and FCF. Moderate upside supports BUY, but utilization/regulatory risk caps confidence. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Higher-than-expected medical loss ratios", "Adverse Medicare or Medicaid rate actions", "Membership losses in key state contracts", "Regulatory or antitrust scrutiny", "Execution missteps in Carelon integration" ], "ticker": "ELV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Margins stabilize as Medicaid pressure eases and services grow.", "target_price": 356 }, "bear": { "prob": 0.25, "notes": "Utilization stays elevated and repricing lags cost trend.", "target_price": 285 }, "bull": { "prob": 0.25, "notes": "Utilization normalizes faster and valuation rerates toward historical ranges.", "target_price": 410 } }, "confidence": 0.66, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.075, "terminal_multiple": 14.5, "ebit_margin_target": 0.041 }, "key_drivers": [ { "driver": "Medicaid redetermination normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare Advantage utilization trend", "impact": "HIGH", "direction": "NEG" }, { "driver": "Premium rate repricing", "impact": "HIGH", "direction": "POS" }, { "driver": "Carelon services growth", "impact": "MED", "direction": "POS" }, { "driver": "Commercial membership retention", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory reimbursement changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Low forward valuation rerating", "impact": "MED", "direction": "POS" }, { "driver": "Balance sheet leverage", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Used snapshot quote/fundamentals as authoritative. 12M target is an earnings-power valuation with modest margin recovery and ~14.5x multiple, cross-checked to EV/EBITDA and FCF. Moderate upside supports BUY, but utilization/regulatory risk caps confidence. not investment advice", "current_price": 318.23, "recommendation": "BUY", "thesis_bullets": [ "Low-teens valuation already discounts utilization and Medicaid mix pressure.", "Medicaid recertification headwinds should moderate over the next year.", "Carelon adds service-driven earnings beyond core insurance underwriting.", "Medical cost trend remains the key swing factor for margins.", "Strong cash generation and dividend support downside resilience." ], "target_price_6m": 338, "target_price_12m": 356 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_026520ac0dff77260069d75880699881909a380052edb692a2", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 29245, "createdAt": "2026-04-09T05:20:32.864Z", "usage": { "inputTokens": 2431, "outputTokens": 1469, "costUsd": 0.02482 } }, { "id": "cmnr13hid03hip658bnpngxeb", "runId": "cmnr13hia03hep658841u5gsy", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"ELV\",\n \"currency\": \"USD\",\n \"current_price\": 318.23,\n \"target_price_6m\": 340,\n \"target_price_12m\": 365,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Scale leader with 47M members in Blue Cross plans\",\n \"12% revenue growth from government program membership\",\n \"Forward P/E 13.7x below historical average\",\n \"Carelon services drive revenue diversification\",\n \"Low beta defensive model balanced by cost risks\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Govt program membership expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical cost inflation trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Carelon specialty services growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory policy shifts\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating efficiency gains\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medicare Advantage competition\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Investment income on float\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Medical costs exceeding premiums\",\n \"Government reimbursement cuts\",\n \"Heightened regulatory oversight\",\n \"Economic impacts on enrollment\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.085,\n \"ebit_margin_target\": 0.04,\n \"wacc\": 0.085,\n \"terminal_multiple\": 14\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 270,\n \"prob\": 0.3,\n \"notes\": \"Elevated loss ratios and regulatory pressures reduce earnings.\"\n },\n \"base\": {\n \"target_price\": 365,\n \"prob\": 0.5,\n \"notes\": \"Stable margins and membership growth at current multiples.\"\n },\n \"bull\": {\n \"target_price\": 430,\n \"prob\": 0.2,\n \"notes\": \"Accelerated Carelon growth with margin expansion.\"\n }\n },\n \"method_notes\": \"DCF using assumed revenue CAGR, EBIT margin, WACC and terminal multiple. 12M target implies ~15% upside consistent with BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Medical costs exceeding premiums", "Government reimbursement cuts", "Heightened regulatory oversight", "Economic impacts on enrollment" ], "ticker": "ELV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Stable margins and membership growth at current multiples.", "target_price": 365 }, "bear": { "prob": 0.3, "notes": "Elevated loss ratios and regulatory pressures reduce earnings.", "target_price": 270 }, "bull": { "prob": 0.2, "notes": "Accelerated Carelon growth with margin expansion.", "target_price": 430 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.085, "terminal_multiple": 14, "ebit_margin_target": 0.04 }, "key_drivers": [ { "driver": "Govt program membership expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical cost inflation trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Carelon specialty services growth", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory policy shifts", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operating efficiency gains", "impact": "MED", "direction": "POS" }, { "driver": "Medicare Advantage competition", "impact": "MED", "direction": "NEG" }, { "driver": "Investment income on float", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF using assumed revenue CAGR, EBIT margin, WACC and terminal multiple. 12M target implies ~15% upside consistent with BUY. Not investment advice.", "current_price": 318.23, "recommendation": "BUY", "thesis_bullets": [ "Scale leader with 47M members in Blue Cross plans", "12% revenue growth from government program membership", "Forward P/E 13.7x below historical average", "Carelon services drive revenue diversification", "Low beta defensive model balanced by cost risks" ], "target_price_6m": 340, "target_price_12m": 365 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "0ebfdb6e-1612-93dc-82a7-949561fbef41", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 11081, "createdAt": "2026-04-09T05:20:32.864Z", "usage": { "inputTokens": 2772, "outputTokens": 2773, "costUsd": 0.049911 } } ] } }